Skip to main navigation
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact

News

BioWorld Insider Podcast: Looking ahead to 2023: CEOs contemplate the new normal
December 5, 2022
Positive results announced from phase 2 trial of oral MS therapeutic
December 1, 2022
Use of Nanoparticles to Combat Neurodegenerative Disease
November 10, 2022
CNM-Au8 Shows Survival Benefit in HEALEY Trial: New Top-line Results
October 4, 2022
HEALEY ALS director says Clene warrants Phase III test despite miss
October 3, 2022
CNM-Au8 Slows Disease Progression in ALS in RESCUE-ALS Phase 2 Trial
October 1, 2022
Clene Energy: Nanocrystal Developer Pursues Remyelination vs. MS, ALS
September 27, 2022
Early CNM-Au8 Continues to Show Survival Benefits in ALS Patients
September 27, 2022
CNM-Au8’s Impact on Survival, Energetic Dysfunction in ALS: Michael Hotchkin
September 23, 2022
CNM-Au8 Displays Evidence of Survival Benefit in Amyotrophic Lateral Sclerosis
September 22, 2022

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Next page next ›
  • Last page last »


1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved